NXL

NXL

USD

Nexalin Technology Inc. Common Stock

$1.790-0.005 (-0.279%)

リアルタイム価格

Healthcare
医療機器
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$1.795

高値

$1.820

安値

$1.741

出来高

0.00M

企業ファンダメンタルズ

時価総額

23.8M

業種

医療機器

United States

取引統計

平均出来高

0.15M

取引所

NCM

通貨

USD

52週レンジ

安値 $0.53現在値 $1.790高値 $4.49

AI分析レポート

最終更新: 2025年4月29日
AIによる生成データソース: Yahoo Finance, Bloomberg, SEC

NXL: Nexalin Technology Inc. Common Stock - What's Happening and What to Watch

Stock Symbol: NXL

Generate Date: 2025-04-29 10:23:21

Let's break down what's been going on with Nexalin Technology stock lately. We'll look at the recent news, check out how the price has moved, and see what some automated analysis suggests might come next.

Recent News Buzz

The news coming out about Nexalin Technology recently feels pretty positive.

Just last week, the company announced they finished a big chunk (Phases One through Five) of their virtual clinic and digital system for their HALO™ product. This sounds like a step forward in how they plan to manage clinical research and help patients, which is generally seen as a good thing for a medical device company trying to get its products out there.

A little earlier in April, they also got a patent from the U.S. Patent Office for their core technology (DIFS™) specifically for treating substance use disorders. Patents are important because they protect a company's ideas and technology, especially in the medical field. Getting one for something like addiction treatment could open up new possibilities for them down the road.

So, on the news front, things seem to be moving in the right direction with progress on their platform and protecting their tech.

Checking the Price Chart

Looking at the stock's price over the last month or so, it's been a bit of a ride. Back in late March, shares were trading higher, around the $2.40-$2.50 mark. Then, the price drifted lower through early April, hitting lows around $1.50.

Interestingly, the price saw a noticeable jump right around the time of that patent news on April 14th, with a lot more shares changing hands that day. But that spike didn't hold, and the price settled back down.

Since the middle of April, the stock has been trading in a tighter range, mostly between $1.60 and $1.80. The last recorded price was $1.82. Volume has been somewhat inconsistent but picked up a bit recently compared to earlier in the month.

Now, what about the future? An AI model that looks at this stuff predicts small increases for the next few days – something like less than 1% today, then a bit over 1% the next day, and around 1.7% the day after that. This suggests the AI sees a slight upward nudge coming in the very near term.

What This Might Mean

Putting the pieces together – the positive news, the stock price stabilizing after a dip, and the AI predicting small near-term gains – the current situation seems to lean slightly positive, at least in the short term.

The news about the virtual clinic and the patent are solid developments for the company. While the stock price dropped through early April, it seems to have found a floor and is now trading sideways, perhaps digesting that news and waiting for the next catalyst. The AI's prediction, while modest, points to a potential slight upward movement from here.

Based on this, and looking at some of the automated analysis, the current price area, around $1.80 to $1.83, could be a level some investors might consider watching for a potential entry. This range aligns with where the stock has been trading recently and is suggested as a potential entry point by some analysis.

If you were considering this stock, managing risk is always key, especially with smaller companies like this one (it has a relatively small market value and low trading volume, which can make the price jump around). A potential level to think about for cutting losses, or a stop-loss, might be around $1.65. This is below recent trading lows and a level highlighted in some analysis.

On the flip side, if the stock does start to move up, a potential target price to watch could be around $2.14. This level is suggested as a possible take-profit point based on the analysis.

Quick Company Context

Just remember, Nexalin is a small company focused on developing medical devices for mental health and substance abuse. Their success really depends on getting their technology through trials and approved, and the recent news about the virtual clinic and the patent are steps in that process. Being a small company means the stock price can be quite sensitive to news and market shifts.


Disclaimer: This analysis is based on the provided data and is for informational purposes only. It is not financial advice. Stock investing involves risk, and you could lose money. Always do your own thorough research or consult with a qualified financial advisor before making any investment decisions.

関連ニュース

GlobeNewswire

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

HOUSTON, TX, May 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin"), today announced that it plans to submit a Q-Submission ("Q-Sub") to the U.S. Food and Drug

もっと見る
Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
GlobeNewswire

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

HOUSTON, TX, April 23, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today

もっと見る
Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
GlobeNewswire

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

HOUSTON, TX, April 14, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is pleased

もっと見る
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

AI予測Beta

AI推奨

強気

更新日時: 2025年5月5日 02:06

弱気中立強気

63.0% 信頼度

リスクと取引

リスクレベル4/5
高リスク
適しているのは
バリュー成長アグレッシブ
取引ガイド

エントリーポイント

$1.76

利確

$2.13

損切り

$1.64

主要因子

PDI 34.0はMDI 26.6の上にあり、ADX 7.7とともに強気トレンドを示唆しています
現在の価格はサポートレベル(1.77ドル)の近くにあり、潜在的な買い機会を示唆しています
MACD 0.0058はシグナルライン0.0033の上にあり、強気クロスオーバーを示しています

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。